Skp2 (S-phase kinase-associated protein-2) SCF complex displays E3 ligase activity and oncogenic activity by regulating protein ubiquitination and degradation, in turn regulating cell cycle entry, senescence and tumorigenesis. The maintenance of the integrity of Skp2 SCF complex is critical for its E3 ligase activity. The Skp2 F-box protein is a rate-limiting step and key factor in this complex, which binds to its protein substrates and triggers ubiquitination and degradation of its substrates. Skp2 is found to be overexpressed in numerous human cancers, which has an important role in tumorigenesis. The molecular mechanism by which the function of Skp2 and Skp2 SCF complex is regulated remains largely unknown. Here we show that Foxo3a transcription factor is a novel and negative regulator of Skp2 SCF complex. Foxo3a is found to be a transcriptional repressor of Skp2 gene expression by directly binding to the Skp2 promoter, thereby inhibiting Skp2 protein expression. Surprisingly, we found for the first time that Foxo3a also displays a transcription-independent activity by directly interacting with Skp2 and disrupting Skp2 SCF complex formation, in turn inhibiting Skp2 SCF E3 ligase activity and promoting p27 stability. Finally, we show that the oncogenic activity of Skp2 is repressed by Foxo3a overexpression. Our results not only reveal novel insights into how Skp2 SCF complex is regulated, but also establish a new role for Foxo3a in tumor suppression through a transcriptiondependent and independent manner.
INTRODUCTION
Skp2 (S-phase kinase-associated protein-2) belongs to the F-Box protein family that forms a complex with Skp1, Cullin1 (Cul-1) and Rbx1 to constitute the Skp2 SCF complex. 1, 2 The Skp2 SCF complex displays ubiquitin ligase (E3) activity, which binds to protein substrates and triggers their ubiquitination and proteosome-dependent degradation. Skp2 recognizes protein substrates and brings them to the Skp2 SCF complex for subsequent ubiquitination and degradation. 1, 2 Although several proteins have been reported to be Skp2 substrates, p27, a cell-cycle inhibitor, is most well characterized and represents a physiological target for Skp2. This notion is supported by the genetic evidence showing that Skp2 À/À MEFs display elevated p27 protein levels and a marked defect in proliferation, and concomitant loss of p27 rescues proliferative defects and reduction in body and organ size observed in Skp2 À/À mice. 3, 4 Importantly, Skp2 is found to overexpress in a variety of human cancer and associate with cancer metastasis, 1, 2, 5 suggesting that Skp2 overexpression may contribute to cancer development and metastasis. In support of this notion, we found that Skp2 overexpression promotes cancer development and metastasis by regulating p27 expression and RhoA expression. 6, 7 Moreover, using the genetic mouse tumor models, Skp2 deficiency profoundly restricts cancer development by regulating either cellular senescence or apoptosis depending on distinct cell and tissue contexts. 8, 9 Thus, Skp2 displays an oncogenic activity, targeting which may be a promising therapeutic strategy for cancer treatment. Skp2 level is tightly orchestrated during the cell cycle. It is low in early G1 phase, but increases at the G1 to S phase transition, which inversely correlates with the level of Cdh1, a coactivator for the ubiquitin ligase anaphase-promoting complex/cyclosome. The degradation of Skp2 is regulated by Cdh1 through Cdh1-mediated ubiquitination and degradation. 10, 11 Although Skp2 has a critical role in cell-cycle transition and oncogenic activity, how Skp2 gene expression and its protein activity are regulated remains largely unclear. Understanding the molecular mechanism by which Skp2 gene expression and Skp2 SCF E3 ligase activity are orchestrated may result in an important therapeutic application.
Foxo3a is a Forkhead box (Fox) transcription factor that contains a conserved DNA-binding domain capable of binding to DNA to induce or repress gene expression. Overexpression of Foxo3a causes cell-cycle arrest and apoptosis by inducing or repressing expression of several genes such as p27, Bim, FasL and Gadd45. 12, 13 Interestingly, loss of Foxo3a expression or cytosolic relocalization is found in various human cancer types.
14 Overexpression of Foxo3a inhibits breast cancer development, whereas silencing its expression promotes breast cancer development in xenograft model. 14, 15 These results suggest that loss of Foxo3a functions may contribute to cancer development. Interestingly, Foxo3a activity is negatively regulated by oncogenic kinases, such as Akt, IKK and ERK, 12, 13 which are known to be activated in human cancers, raising the possibility that these oncogenic kinases may trigger Foxo3a inactivation during cancer development.
In this study, we aim to decipher the mechanism by which Skp2 gene expression and the formation of Skp2 SCF complex are regulated. We find here that Foxo3a is not only a novel transcriptional repressor for Skp2 gene expression, but also a repressor for the formation of Skp2 SCF complex, offering a new mechanistic insight into how Foxo3a may display a tumor suppressive activity. 16 for Foxo3a, a tumor suppressor involved in cell-growth arrest and apoptosis. 12, 13 We therefore hypothesized that Foxo3a may be a transcription factor that regulates Skp2 gene expression.
RESULTS

Foxo3a is
To test this hypothesis, we performed the luciferase reporter assay to examine whether Foxo3a regulates Skp2 promoter activity and found that overexpression of Foxo3a significantly reduced the Skp2 promoter activity (Figures 1a and b) . To further test the specificity of the Foxo3a-mediated transcriptional repression of the Skp2 promoter, we applied both the DNA-binding mutant (DBM) form of Foxo3a, Foxo3a-H212R, which cannot bind to the consensus Forkhead responsive element, 17 and the mutant Skp2 promoter construct, which harbors mutations in two potential Foxo3a consensus binding sites, to the luciferase reporter assay. As shown in Figures 1a and b , while Foxo3a suppressed the Skp2 promoter activity (68.3% reduction), Foxo3a-DBM compromised this activity (38.6% reduction), indicating that Foxo3a is a transcriptional repressor of Skp2. Surprisingly, Foxo1, another member of the Foxo family transcription factors, failed to suppress Skp2 promoter activity (Figure 1a, lane 5) . As for the mutant Skp2 promoter, the suppression effect of Foxo3a-WT on the Skp2 promoter activity was reduced by the mutations of the identified Foxo3a binding sites, and the reduction rate was dropped from 68.3 to 53.6% (Figures 1a and b) . Both moderately compromised effects highly suggest that there are likely other unrecognized non-consensus Foxo3a binding sites present within the B4-kb Skp2 promoter. The defective function of Foxo3a-DBM was confirmed using the p27 promoter luciferase construct in Figure 1c . To determine whether Foxo3a is a transcription repressor that directly binds to Skp2 promoter, we next performed the ChIP assay and found that Foxo3a directly bound to the Skp2 promoter region (Figures 1d and e) . Accordingly, our results suggest that Foxo3a is a novel transcriptional repressor for Skp2.
To rule out the possibility of Foxo3a-mediated repression of Skp2 gene expression may be due to the overexpression artifact, we therefore used the lentiviral infection system to knock down Foxo3a expression. In support of the notion that Foxo3a is a negative repressor for Skp2 gene expression, the real-time PCR result revealed that Foxo3a knockdown profoundly enhanced the level of Skp2 mRNA ( Figure 2a ). As a positive control, we showed that Foxo3a knockdown reduced p27 mRNA level, consistent with the fact that Foxo3a is a transcription factor for p27 (Figure 2b) . Similarly, Foxo3a knockdown also markedly promoted Skp2 protein expression (Figure 2c ). Taken together, these results suggest that Foxo3a is a transcription repressor for Skp2 gene expression. Next, we further examined whether Akt signaling, which has been shown to positively regulate Skp2 expression, 18 --20 has an impact on Foxo3a transcription-dependent activity on Skp2. As shown in Figure 2d , while constitutively activated Akt (Myr-Akt) upregulated Skp2 protein level (comparing lanes 1 and 2) in GFP control knockdown cells, it failed to induce Skp2 expression in Foxo3a knockdown cells (comparing lanes 3 and 4). As Akt is known to downregulate Foxo3a activity, this result suggests that the effect of Akt on Skp2 expression is likely through its effect on Foxo3a inhibition.
Foxo3a interacts with Skp2 and inhibits Skp2 SCF E3 ligase activity As aforementioned, Skp2 is an F-box protein that forms the Skp2 SCF complex with Skp1, Cul-1 and Rbx1 to constitute an E3 ligase activity. The Skp2 SCF E3 ligase activity is required for Skp2's oncogenic activity. The factor controlling Skp2 SCF complex formation presumably affects Skp2 SCF E3 ligase activity. Skp2 is shown to interact with Foxo1 and target it for ubiquitination and degradation. 21 We therefore determined whether Skp2 may interact with Foxo3a as well. In vivo co-immunoprecipitation (IP) experiments revealed that endogenous Foxo3a could form a complex with endogenous Skp2, and their interaction was profoundly attenuated by Foxo3a knockdown (Figure 3a) .
As Foxo3a interacts with Skp2 under a physiological condition, we next sought to determine whether Foxo3a regulates Skp2 E3 ligase activity. To this goal, we performed both the in vivo and in vitro p27 ubiquitination assays to determine whether Foxo3a regulates Skp2-mediated p27 ubiquitination. Figure 3b showed that p27 underwent the basal ubiquitination in the mocktransfected cells, and Skp2 overexpression readily promoted p27 ubiquitination in vivo. Notably, Foxo3a overexpression suppressed Skp2-mediated p27 ubiquitination (Figure 3b ). In addition, the presence of Foxo3a inhibited Skp2-mediated ubiquitination of p27 in the in vitro system (Figure 3c ). Therefore, Foxo3a interacts with Skp2 and negatively regulates Skp2 SCF E3 ligase activity.
Foxo3a negatively regulates the formation Skp2 SCF complex In support of this notion that Foxo3a regulates Skp2 SCF E3 ligase activity, we found that Foxo3a knockdown markedly promoted endogenous p27 degradation compared with control knockdown (Figure 3d ), revealing that higher Skp2 SCF E3 ligase activity is present in Foxo3a knockdown cells. Strikingly, Skp2 silencing completely rescued p27 stability in Foxo3a knockdown cells (Figure 3d ). Accordingly, these results underscore the important role of Foxo3a in suppressing Skp2 SCF E3 ligase activity, in turn promoting p27 stability.
Skp2 SCF E3 ligase activity is tightly regulated by the integrity of Skp2 SCF complex. As our result showed that Foxo3a represses Skp2 SCF E3 ligase activity, it is conceivable that Foxo3a may regulate the formation of Skp2 SCF complex. Indeed, Foxo3a overexpression inhibited the ability of Skp2 to interact with Skp1 and Cul-1 (Figure 4a) . Surprisingly, transcription-deficient mutant of Foxo3a (Foxo3a-DBM) also possesses the same ability to impair the formation of the Skp2-SCF complex (Figure 4a ), suggesting a novel transcription-independent function of Foxo3a in disassembling Skp2-SCF complex. Conversely, Foxo3a knockdown promoted the interaction of Skp2 with Skp1 and Cul-1 (Figure 4b ). Taken together, our results suggest that Foxo3a interacts with Skp2 and prevents the formation of Skp2 SCF complex, in turn suppressing Skp2 SCF E3 ligase activity.
Foxo3a inhibits Skp2-mediated cell proliferation Skp2 displays an oncogenic activity by targeting p27 ubiquitination and degradation. As Foxo3a inhibits Skp2 SCF E3 ligase toward p27 ubiquitination and degradation, we next determined whether Foxo3a has an impact on Skp2-mediated cell proliferation. To this end, we applied the growth curve assay and the BrdU incorporation assay to examine cell proliferation. We found that, as expected, Skp2 overexpression profoundly promoted cell proliferation ( Figure 5 ). Strikingly, introduction of Foxo3a markedly suppressed Skp2-mediated cell proliferation ( Figure 5 ). Therefore, our results suggest that Foxo3a negatively regulates Skp2-mediated cell proliferation.
DISCUSSION
Although there are redundant roles among Foxo family transcription factors, the mice deficient for all Foxo transcription including Foxo1, Foxo3 and Foxo4 develop thymic lymphomas and hemangiomas, 22 suggesting that Foxo family transcription factors are bona fide In line with this notion, Foxo3a is shown to display tumor suppressive activity, the overexpression of which induces cellcycle arrest and apoptosis, whereas its silencing promotes cell growth and survival. As a transcription factor, Foxo3a is generally thought to function as a tumor suppressor in a manner dependent on its transcriptional activity. Foxo3a triggers cell-cycle arrest by inducing p27 and p21 gene expression, whereas it turns on Bim, FasL and GADD45 to elicit apoptosis. 12, 13 Whether Foxo3a-mediated tumor suppressive functions can also function through its transcriptionindependent activity remains largely unknown. Our finding showing that Foxo3a interacts with Skp2 and disrupts the formation of Skp2 SCF complex and Skp2 SCF E3 ligase activity reveals a novel transcription-independent activity of Foxo3a in tumor suppression.
Although several transcription factors, such as E2F1, 23 NF-kB, 24 ,25 SP1, 26 CBF1, 27 GABP (GA-binding protein) 28 and FoxM1, 29 can serve as transcription factors for Skp2, little is known about the transcription repressors for Skp2. In this study, we present the evidence that Foxo3a is a transcription repressor for oncogenic Skp2. Our study therefore provides a clue to this puzzle and reveals that Foxo3a is a novel transcription repressor for Skp2. As Skp2 level is known to be regulated by growth factors or serum stimulation, which also repress Foxo3a expression, it is formally possible that these stimuli may inhibit Foxo3a expression, in turn promoting Skp2 gene expression.
Interestingly, Foxp3, a Fox transcription factor, is also shown to bind to Skp2 promoter and represses Skp2 gene expression; 30 therefore, Skp2 gene expression may be generally repressed by Fox transcription factors. However, this may not be a general phenomenon as we show that Foxo1 fails to suppress Skp2 gene expression (Figure 1a) . Nevertheless, it requires more thorough analysis to examine whether other Foxo family transcription factors can also serve as Skp2 transcription repressors.
Notably, PTEN/Akt signaling is known to regulate Skp2 gene expression, although the molecular mechanism responsible for it remains to be determined. As Akt kinase is known to phosphorylate Foxo3a and repress its transcription activity, it is highly possible that Akt induces Skp2 gene expression through phosphorylating and inhibiting Foxo3a activity. Consistent with this notion, we demonstrate that Akt may regulate Skp2 gene expression through its effect on Foxo3a inhibition (Figure 2d ). The integrity of Skp2 SCF complex formation is important for Skp2 SCF E3 ligase activity; however, how this complex is regulated remains largely unclear. Earlier studies showed that neddylation of Cul-1 positively regulates Skp2 SCF complex formation and its E3 ligase activity by preventing the binding of Cul-1 to Cand1, a negative regulator for the Skp2 SCF complex. Cand1 preferentially interacts with unneddylated Cul-1, thus preventing Cul-1 from binding to Skp1 and Skp2. 31 --33 In addition, the formation of the Skp2 SCF complex can be induced by the PI3K/Akt signal, 34 and recent studies reveal that Akt interacts with Skp2 and induces S72 phosphorylation of Skp2, which is critical for Skp2 stability, Skp2 SCF complex formation and Skp2 SCF E3 ligase activity. 7, 35 How Skp2 phosphorylation at Ser 72 regulates Skp2 SCF complex and its E3 ligase activity is not yet clear.
Our study identifies Foxo3a as a novel, negative regulator for Skp2 SCF complex and its E3 ligase activity. We show that Foxo3a overexpression disrupts the Skp2 SCF complex formation, whereas Foxo3a silencing promotes it. The inhibitory effect of Foxo3a on Skp2 SCF complex formation is independently of its transcriptional activity, as the transcriptional deficient mutant of Foxo3a can still repress Skp2 SCF complex formation as efficiently as wild-type Foxo3a does (Figure 4a ). Our result therefore reveals a novel, previously unrecognized transcription-independent activity of Foxo3a in disassembling Skp2 SCF complex. It is likely that Foxo3a may interrupt the interaction between Skp2 and Skp1 by directly interacting with Skp2. Another possibility is that Foxo3a may bind to Skp2 and recruits Cand1 to the Skp2 complex, in turn preventing Skp2 SCF complex formation. Importantly, our study offers another potential explanation for how PI3K/Akt regulates Skp2 SCF complex. We speculate that PI3K/Akt may trigger Foxo3a phosphorylation and prevents Foxo3a/ Skp2 interaction, thereby facilitating Skp2 SCF complex formation. Interestingly, Foxo3a, similar to Foxo1, is reported to be a substrate for Skp2. 36 We postulate that upregulated Skp2 SCF E3 ligase activity by PI3K/Akt can further inhibit Foxo3a function through promoting ubiquitination and degradation of Foxo3a.
p27 displays tumor suppressive activity by inducing cell-cycle arrest and senescence. 8, 37, 38 The expression of p27 is frequently reduced and/or lost during cancer progression, which inversely correlates with Skp2 expression.
39 --41 p27 gene expression is known to be orchestrated by Foxo3a.
42 Foxo3a serves as a transcription factor for p27 by binding to the p27 promoter region and induce p27 gene expression. Importantly, our study suggests that Foxo3a not only regulates p27 gene expression, but also controls p27 stability. We show that Foxo3a promotes p27 stability by disrupting the formation of Skp2 SCF complex and Skp2 SCF E3 ligase activity. Thus, our study reveals a novel insight into how Foxo3a displays tumor suppressive activity. Given that Foxo3a is often inactivated in human cancers, it is likely that the loss of p27 expression seen in advanced human cancers may be, in part, due to the loss or inactivation of Foxo3a.
In summary, our findings reveal that Foxo3a is not only a novel transcription repressor for Skp2, but also a negative regulator for Skp2 SCF complex formation and its E3 ligase activity, in turn promoting p27 stability. Our study therefore provides an important mechanistic insight into how Foxo3a orchestrates cellcycle arrest and survival, thereby favoring tumor suppression.
METHODS
Cell culture and reagents
HEK293T, HEK293, DU145, PC-3, HeLa and COS-1 cells were cultured in DMEM containing 10% fetal bovine serum. Xp-Skp2, HA-Myr-Akt, His-ubiquitin and pcDNA3-p27 plasmids were described previously. 7 HA-Foxo3a-WT, HAFoxo3a-DBM (Addgene plasmid no. 8352; Addgene, Cambridge, MA, USA) and HA-Foxo1 (Addgene plasmid no. 10693) plasmid were gifts from Drs ME Greenberg and WR Sellers. The Skp2 promoter plasmid, kindly provided by Dr VA Boussiotis, was described elsewhere. 26 The mutant Skp2 promoter construct was generated by the site-directed mutagenesis kit (Stratagene, Santa Clara, CA, USA) in accordance with the manufacturer's standard procedure using the wild-type Skp2 promoter construct as a template.
Skp2 reporter assay
HEK293T cells were transfected with indicated plasmids by using Lipofectamine 2000 (Invitrogen/Life Technologies, Carlsbad, CA, USA) for 48 h, and the luciferase activity was measured by using the dual luciferase system (Promega, Madison, WI, USA) as described elsewhere. 6, 43 Each sample was analyzed in triplicate. The relative luciferase activity was expressed as a ratio of the firefly luciferase activity to the Renilla luciferase activity. 
ChIP assay
The ChIP assay was performed according to the manufacturer's instructions (Upstate/Millipore, Temecula, CA, USA). 6 A DNA-protein complex was sheared by sonication. One percent of sheared DNA-protein complex was kept as an input DNA sample. Anti-Foxo3a (Cell Signaling, Danvers, MA, USA), anti-GFP (Cell Signaling) (as rabbit control IgG), anti-RNA polymerase II (Upstate) and normal mouse IgG (Upstate) were used for IP. Standard PCR was performed using primers: Skp2 forward primer (5 0 -CTGTACTCTAC ATGGGAAAAGTGG-3 0 ) and Skp2 reverse primer (5 0 -TATTCTCTGTGGTGG TGGCAGCTA-3 0 ). PCR products were run in 1% agarose gel. Enrichment of promoter binding levels was also analyzed by real-time PCR in triplicate and expressed as a percentage relative to the input. The quantified result is presented as mean±s.d.
Real-time RT --PCR
Total RNA was isolated from GFP control and Foxo3a-knockdown DU145 cells with TRIzol (Invitrogen). cDNA was synthesized by using the SuperScript First-Strand Synthesis System (Invitrogen). Skp2 and p27 
Viral infection
For lentiviral short-hairpin RNA (shRNA) infection, HEK293T cells were co-transfected with shRNAs against GFP, Foxo3a or Skp2 along with the packing plasmid (deltaVPR8.9), and the envelope plasmid (VSV-G) using the calcium phosphate precipitation method. Two days after transfection, virus particles were used to infect the indicated cell lines. All the infected cells were selected in the medium containing 2 mg/ml puromycin for 5 --7 days. The following lentiviral shRNAs were used for transfection: Skp2- 
IP and immunoblotting (IB)
IP and IB were done essentially as described with mild modification. 6, 44 For IP, cells were lysed in E1A lysis buffer (250 mM NaCl, 50 mM HEPES (pH 7. 
Ubiquitination assays
The in vivo ubiquitination assay was performed as described elsewhere. 6, 7 In brief, HEK293T cells were transfected with the indicated plasmids for 48 h, treated with MG132 for 6 h, and lysed with denaturing buffer (6 M guanidine-HCl, 0.1 M Na 2 HPO 4 /NaH 2 PO 4 , 10 mM imidazole), followed by nickel bead purification and IB analysis. For p27 in vitro ubiquitination assay, Flag-Skp2 and HA-Foxo3a were isolated individually from HEK293T cell extracts and eluted from beads by FLAG and HA peptides (Sigma) respectively, followed by concentration with Amicon (Millipore, Temecula, CA, USA). The p27 protein was immunoprecipitated from the cell extract of HEK293T transfected with pcDNA3-p27, and then incubated with ubiquitin, E1, E2 enzymes (Boston Biochem, Cambridge, MA, USA) and purified Flag-Skp2 in ubiquitination buffer (20 mM Hepes (pH7.4), 1.5 mM MgCl 2 , 5 mM KCl, 1 mM DTT, 1 mM ATP, protease inhibitor cocktail (Roche)) in the presence or absence of purified HA-Foxo3a. Ubiquitination reaction was carried out at 37 1C for 2 h on a rotator and terminated by washing the pellets. Ubiquitinated p27 was analyzed by IB with antiubiquitin antibody.
MTT proliferation assay
HeLa cells were transfected with the indicated plasmids for 24 h, then were plated in 96-well plate (3000 cells per well). In the following three days, cells were incubated with MTT (Thiazolyl Blue Tetrazolium Bromide) for 4 h. After incubation, culture medium was removed, and then the equal volume of DMSO was added to each well. Absorbance was measured by a spectrophotometer at 570 nm after shaking for 10 min.
BrdU incorporation assay
BrdU incorporation assay was performed with the in situ cell proliferation kit, FLUOS (Roche), and the manufacturer's instructions were followed. In brief, COS-1 cells seeded on chamber slides were transfected with the indicated plasmids. At 24 h post transfection, the cells were serum-starved for 24 h, and then refreshed with 10% fetal bovine serum for 18 h. Following incubation with 10 mM bromodeoxyuridine (BrdU) for 1 h, the cells were subjected to immunostaining for detection of BrdU incorporation. The percentages of BrdU-positive cells were scored. The representative images were shown and the quantified result was presented as mean±s.d.
